Strides started in 1990 with the goal of building a pharmaceutical company from India that could make a difference around the world. From humble beginnings to a global healthcare partner, our journey has been one of growth, resilience, and continuous progress. What began as a small entrepreneurial venture has grown into a global pharmaceutical powerhouse. From our humble beginnings, we at Strides Pharma have expanded our presence to over 100 countries, driven by a singular vision: to touch lives and transform health. Since 1990, this vision has guided every step we take, fuelling our unwavering commitment to advancing healthcare and improving patient outcomes worldwide. At the heart of Strides is our deep-rooted purpose to make high-quality, accessible healthcare a reality for all. This purpose is reflected in every product we create, every partnership we build, and every community we touch through our care. With our headquarters in Bengaluru, India, we operate with a dual focus on regulated and emerging markets, ensuring that life-saving medicines reach those who need them the most, no matter where they are. We believe that collaboration is the cornerstone of progress. Synergice is our dedicated B2B platform, built on the principle of "Leadership through Partnering." Designed to meet diverse portfolio needs, Synergice brings together the full breadth of Strides Pharma's offerings in over 100 countries. Our unwavering commitment is to build enduring partnerships while delivering solutions that meet the unique requirements of our valued partners. The platform empowers partners with access to advanced manufacturing capabilities, robust regulatory expertise, and innovative pharmaceutical solutions. More than just a platform, Synergice is a dynamic B2B ecosystem, a reflection of the belief that collaboration transforms potential into progress. By working side by side, we enable our partners and the communities they serve to achieve more and make more possible.
2002-Board approves for the allotment of 210,955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd.
-Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route.
-Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act.
-Incorporates 'Strides Africa Ltd' at British Virgin Island with an authorised capital of US $ 200,000 as 100% wholly owned subsidiary.
-Board decides to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations.
2003
-Nominates Mr Francis Pinto as the Director on the Board of the company.
-Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems.
-Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical products.
-Changes in the Management:
Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr Krishna Kumar Menon as COO.
-Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company.
-Strides inks MoU with Ribbon SRL for Cephalosporin
2004
-Major Fire occurs in Private Custom Bonded warehouse in Mexico
-Strides Arcolab Limited has entered into a memorandum of understanding with BITS, Pilani for an ``off campus collaborative programme'. As part of the partnership, Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job.
2005
- Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets.
-Strides Arcolab enters into an agreement for private placement issue
- Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs
-Strides acquires sterile manufacturing facility in Poland
2007
- Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets, an anti-HIV drug. Efavirenz, is the generic version of Bristol Myers Squibb's Sustiva, which helps in preventing the HIV virus from reproduction.
- Strides Arcolab receives 2 more NDA approvals from US-FDA.
2008
- Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials.
2010
- Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been appointed as an Executive Director of the Company.
2011
-Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite
-Strides announces First European Approval for Oncology Product
-Strides Arcolab receives US FDA Nod to Commercialize First Liquid
-StridesArcoL Update on acquisition of outstanding minority shareholding in Ascent Pharmahealth Limited
-Strides Arcolab joins the Malaysian Bio-xcell Ecosystem
2012
-Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile
-Strides Arcolab receives US FDA approval for Methotrexate Injection
-Strides Arcolab Announces Health Canada Approval For Tobramycin Injection
-Strides Arcolab acquires Sterile Formulations facility to expand core injectable biz
-Strides collaborates with Gilead Sciences
2013
-Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet.
- Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility.
- Strides announces WHO pre-qualification for Artemether + Lumifantrine .
-StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology.
-Strides Arcolab - Re-branding Biotech Business as 'Stelis'.
-Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market.
2014
-- Medicines for Malaria Venture announces collaborations with Cipla and Strides.
-Strides Arcolab makes strategic investment in Oncobiologics Inc., USA.
- Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries.
-Strides Arcolab receives US FDA approval for Buspirone Tablets.
-Strides Arcolab receives US FDA approval for Calcitriol Softgel.
-Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna.
-Strides Arcolab to acquire Shasun Pharma in all stock deal.
2015
-Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc
-Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc,
-Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India "Virso"
-Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350
-Strides Arcolab gets USFDA nod for HIV treatment drug
-Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company.
-Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia.
-Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy
-Strides Arcolab Ltd has changed from its present name "Strides Arcolab Limited" to "Strides Shasun Limited"
2016
-Strides Shasun updates on "Acquisition of seven brands from Johnson & Johnson".
-Strides Shasun update on "Acquisition of CNS divisions of erstwhile Ranbaxy".
-"Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia".
-"Strides Shasun to acquire controlling stake in Universal Corporation, Kenya".
-"Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet".
- "Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore".
2017
-Strides Shasun bags approval for Acetazolamide tablets.
-Strides bags approval for Omega-3-Acid Ethyl Esters capsules.
-Strides Shasun gets USFDA nod to launch allergy drug in US.
-Strides Shasun completes JV pact with Vivimed Labs.
2018
-Company name has changed to Strides Pharma Science Ltd. from Strides Shasun Ltd.
-Strides gets USFDA nod for Polyethylene Glycol 3350 and Electrolytes for oral solution.
-Strides' subsidiary inks pact with SUDA Pharmaceuticals for migraine drug.
- Strides gets USFDA nod for Potassium Chloride Extended Release Tab.
2019
-Strides Pharma relaunches Ranitidine tablets in US.
-Strides Pharma Science arm gets USFDA nod for drug to treat overactive bladder.
-Strides Pharma acquires USFDA approved facility in the US.
-Strides inks joint venture pact with China's Sihuan Pharma.
2020
-Strides Pharma Science gets USFDA nod for Prednisone tablets.
-Strides Pharma Science gets USFDA nod for generic anti-bacterial capsules.
-Strides arm receives EIR for its US facility.
2021
-Stelis Biopharma commissions its greenfield vaccine manufacturing facility at Bengaluru.
-Strides, TLC partner to launch black fungus drug in India.
-Strides Pharma arm receives USFDA nod for potassium chloride oral solution.
-Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.
2022
-Strides receives USFDA approval for Potassium Chloride Oral Solution.
-Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules.
-Strides receives USFDA approval for Cyclosporine Softgel Capsules
-Strides receives USFDA approval for Ibuprofen Oral Suspension.
-Strides partners with Medicines Patent Pool (MPP) to commercialize the generic version of Pfizer's COVID-19 Oral Treatment across 95 markets.
2023
-Strides receives USFDA approval for Generic Suprepr Bowel Prep Kit.
-Strides receives USFDA approval for Levetiracetam Oral Solution.
-Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets.
-Strides receives USFDA approval for Icosapent Ethyl Capsules.
-Strides receives tentative USFDA approval for Dolutegravir tablets.
2024 -Strides receives USFDA approval for Fluoxetine Tabs 60 mg; Expanding the Product s Availability Across Strengths.
-Strides Pharma unit gets USFDA nod for generic drug to treat gastrointestinal diseases. -Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg. -Acquisition of balance stake in Strides Global Consumer Healthcare Limited, UK. -Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL -Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg. -Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg.
2025 -De-merger of Identified Business of Arco Lab Private Limited (Arco Lab), a wholly owned subsidiary of the Company -Acquisition of 100% stake in Amexel Pte. Ltd., Singapore by Strides Pharma Global Pte. Limited, -Strides has been honoured at the Great Indian Treasury Leaders Summit and Awards 2025 -Honoured to achieve Top 10% Global Ranking on S&P Global's 2025 Sustainability Yearbook -Strides honoured with the Manufacturing Excellence Award at the DET Hurun 2025 -Strides honoured with the Innovation in Quality Award at the Pharma Quality Excellence Awards 2025
|